Jim Cramer's 8-Point Plan for Higher Stock Prices
Implement these initiatives, said Cramer, and the stock market would rocket to all-time highs and America would be on a much more solid footing with a far brighter future.
In the "Executive Decision" segment, Cramer spoke with Chris Garabedian, president and CEO of Sarepta Therapeutics (SRPT), a small biotech firm that saw its shares soar over 200% after the company announced Wednesday positive data for its muscular dystrophy drug, Eteplirsen. Cramer recommended Sarepta as a speculative stock back on Sept. 21.
Garabedian said his company is very excited about today's news and the market's response to it, as well as what the data mean to patients and their families. He then showed a chart of how patients taking Eteplirsen fared against those taking a placebo over a 48-week period.
The data clearly showed those patients taking the placebo saw a steady progression of the disease until they were no longer able to walk, but those taking Eteplirsen not only stabilized but actually saw improvement in weeks 36 through 48. Sarepta has now switched those taking the placebo to Eteplirsen and is studying how the drug affects people in the later stages of the disease.Garabedian explained that while the data only include Phase II results and the sample size was 12 patients, this is not uncommon for a rare disease. What matters most is how much patients improved while taking the drug. He also responded to criticisms that two patients did not respond to the drug. He said in those cases the disease had already started progressing before the drug could take hold. Garabedian said Sarepta is amenable to taking on partners to help it speed up its Eteplirsen program and expand it overseas, but the company is also preparing to continue developing the drug in-house if necessary. Cramer said results like these don't come from a paycheck, or a bank CD or even a typical stock, they only come from speculating, which is why he has always said that speculation needs to be a part of everyone's portfolio.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV